


# Carbon Ion Radiotherapy for Skull Base and Paracervical Chordomas

Azusa Hasegawa, Jun-etsu Mizoe and Hirohiko Tsujii

*Research Center Hospital for Charged Particle Therapy  
National Institute of Radiological Sciences*

*Corresponding Author: Jun-etsu Mizoe, e-mail address: [j\\_mizoe@nirs.go.jp](mailto:j_mizoe@nirs.go.jp)  
Azusa Hasegawa, e-mail address: [azusa@nirs.go.jp](mailto:azusa@nirs.go.jp)*

# Skull Base and Paracervical Tumors



## Subjects:

Chordoma, meningioma, chondrosarcoma and other tumors originating from skull base or paracervical spine located C1 and C2 vertebra

## Eligibility criteria:

1. Age ranged from 15 to 80 years
2. Measurable and histologically proven tumor
3. KPS: 60% or higher, Neurological Function (NF) : grade 1 or 2
4. Expected prognosis of at least 6 months or longer
5. Absence of prior RT for target
6. Proceeded chemotherapy must be concluded at least 4 weeks before C-ion RT
7. No distant metastasis

# Classification by Carbon Ion Dose and Histological Type

April 1997~August 2007

|                | Total | 48.0GyE | 52.8GyE | 57.6GyE | 60.8GyE |
|----------------|-------|---------|---------|---------|---------|
| Chordoma       | 29    | 1       | 3       | 6       | 19      |
| Chondrosarcoma | 7     | 1       | 0       | 1       | 5       |
| Meningioma     | 6     | 2       | 3       | 0       | 1       |
| ON*            | 3     | 0       | 0       | 1       | 2       |
| GCS**          | 1     | 0       | 0       | 1       | 0       |
| Total          | 46    | 4       | 6       | 9       | 27      |

\* ON: Olfactory neuroblastoma

\*\* GCS: Giant cell sarcoma


# Patients and Treatment Characteristics

April 1997 ~ February 2004    phase I/II clinical trial: 15 cases  
 April 2004 ~ August 2007    phase II: 14 cases

Total of 29 patients

| Gender                    |            | Previous treatment       |              |
|---------------------------|------------|--------------------------|--------------|
| Male/ Female (n)          | 12/ 17     | Surgery                  | 23           |
| Age, years                |            |                          | Subtotal (3) |
| Median (range)            | 47 (16-76) |                          | Partial (15) |
| Tumor sites               |            |                          | Biopsy (5)   |
| Skull base                | 10         | Recurrence after surgery | 6            |
| Clivus                    | 10         | Gross tumor volume, (ml) |              |
| Cervical spine/ paraspine | 7          | Median (range)           | 29.8 (2-328) |
| Other sites               | 2          |                          |              |


Planning CT



MRI




Fusion



Fusion Image

Reconstructed MRI



# Treatment Planning

## 1. Delineation of CTV

- 1) A margin of 3-5mm was usually added to the GTV.
- 2) CTV included the suspected subclinical lesions.
- 3) When the tumor was located close to the brainstem, spinal cord optic chiasma and optic nerves, the margin was reduced.

## 2. Maximum dose for critical organs (PROG)


- 1) Surface of Brainstem and Spinal cord: 60 GyE
- 2) Center of Brainstem and Spinal cord: 50 GyE
- 3) Chiasma and contralateral Optic nerve: 55 GyE

# Retrospective DVH Analysis of Optic Nerve in Carbon Ion Radiotherapy

## Dose-complication probability curves

Treated from June 1994 to March 2000.

Fifty-four ONs with 11 visual loss.



# Retrospective DVH Analysis of Optic Nerve in Carbon Ion Radiotherapy

Treated from June 1994 to March 2000.

Fifty-four ONs with 11 visual loss.

## Result

$D_{\max}$  : 0% (0/35) < 55 GyE < 58% (11/19)

$D_{20}$  : 0% (0/31) < 40 GyE < 48% (11/23)

$D_{\max}$  less than 55 GyE or  $D_{20}$  less than 40 GyE  
were recommended.

( Int. J Radiation Oncology Biol. Phys., Vol. 64, 2006)

# Acute and Late Radiation Morbidities

29 patients

## Acute: Skin

### RTOG

| Dose (n)      | grade 0 | 1  | 2 | 3 |
|---------------|---------|----|---|---|
| 48 GyE (1)    | 0       | 1  | 0 | 0 |
| 52.8 GyE (3)  | 1       | 1  | 1 | 0 |
| 57.6 GyE (6)  | 3       | 3  | 0 | 0 |
| 60.8 GyE (19) | 12      | 7  | 0 | 0 |
| Total (29)    | 16      | 12 | 1 | 0 |

## Late: Skin

### RTOG / EORTC

| Dose (n)      | grade 0 | 1 | 2 | 3 |
|---------------|---------|---|---|---|
| 48 GyE (1)    | 1       | 0 | 0 | 0 |
| 52.8 GyE (3)  | 2       | 1 | 0 | 0 |
| 57.6 GyE (6)  | 5       | 1 | 0 | 0 |
| 60.8 GyE (19) | 19      | 0 | 0 | 0 |
| Total (29)    | 27      | 2 | 0 | 0 |

## Acute: Mucosa

### RTOG

| Dose (n)      | grade 0 | 1 | 2 | 3 |
|---------------|---------|---|---|---|
| 48 GyE (1)    | 1       | 0 | 0 | 0 |
| 52.8 GyE (3)  | 1       | 0 | 2 | 0 |
| 57.6 GyE (6)  | 3       | 3 | 0 | 0 |
| 60.8 GyE (17) | 10      | 3 | 4 | 0 |
| Total (27)    | 15      | 6 | 6 | 0 |

## Late: Mucosa

### RTOG / EORTC

| Dose (n)      | grade 0 | 1 | 2 | 3 |
|---------------|---------|---|---|---|
| 48 GyE (1)    | 1       | 0 | 0 | 0 |
| 52.8 GyE (3)  | 2       | 1 | 0 | 0 |
| 57.6 GyE (6)  | 6       | 0 | 0 | 0 |
| 60.8 GyE (17) | 16      | 1 | 0 | 0 |
| Total (27)    | 25      | 2 | 0 | 0 |

# Acute and Late Radiation Morbidities

29 patients

## Acute: Brain

### RTOG

| Dose (n)      | grade 0 | 1 | 2 | 3 |
|---------------|---------|---|---|---|
| 48 GyE (1)    | 1       | 0 | 0 | 0 |
| 52.8 GyE (3)  | 3       | 0 | 0 | 0 |
| 57.6 GyE (6)  | 6       | 0 | 0 | 0 |
| 60.8 GyE (19) | 19      | 0 | 0 | 0 |
| Total (29)    | 29      | 0 | 0 | 0 |

## Late: Brain

### RTOG / EORTC and LENT SOMA

| Dose (n)      | grade 0 | 1 | 2 |
|---------------|---------|---|---|
| 48 GyE (1)    | 1       | 0 | 0 |
| 52.8 GyE (3)  | 3       | 0 | 0 |
| 57.6 GyE (6)  | 6       | 0 | 0 |
| 60.8 GyE (19) | 14      | 4 | 1 |
| Total (29)    | 24      | 4 | 1 |

Grade 1: Occasional non-narcotic medication  
Grade 2: Persistent non-narcotic medication,  
intermittent low dose steroids

## Acute: Spinal cord

### RTOG

| Dose (n)      | grade 0 | 1 | 2 | 3 |
|---------------|---------|---|---|---|
| 48 GyE (1)    | 1       | 0 | 0 | 0 |
| 52.8 GyE (3)  | 3       | 0 | 0 | 0 |
| 57.6 GyE (6)  | 6       | 0 | 0 | 0 |
| 60.8 GyE (15) | 15      | 0 | 0 | 0 |
| Total (25)    | 25      | 0 | 0 | 0 |



## Late: Spinal cord

### RTOG / EORTC and LENT SOMA


| Dose (n)      | grade 0 | 1 | 2 |
|---------------|---------|---|---|
| 48 GyE (1)    | 1       | 0 | 0 |
| 52.8 GyE (3)  | 3       | 0 | 0 |
| 57.6 GyE (6)  | 6       | 0 | 0 |
| 60.8 GyE (15) | 15      | 0 | 0 |
| Total (25)    | 25      | 0 | 0 |

# Postoperative Chordoma in the Right Clivus



Carbon ion dose: 60.8 GyE/16 frs.





Pre ope




Pre c-ion RT



Dose distribution and PTV



Post op and PTV




G1 Brain Reaction





Post op and PTV

# Postoperative Chordoma in the Right Clivus

Carbon ion dose: 60.8 GyE/16 frs.




Pre c-ion RT



Dose distribution and Reconstructed MRI

# Postoperative Chordoma in the Right Clivus

Carbon ion dose: 60.8 GyE/16 frs.



Pre c-ion RT


Post 20 months

Post 26 months


Post 45 months

# Postoperative Chordoma in the Clivus and Nasopharyngeal Space

Carbon ion dose: 60.8 GyE/16 frs





Pre ope



Pre c-ion RT




Dose distribution




Post 40 months

# Local control of 29 Chordomas



# Overall survival of 29 Chordomas



## *Clinical characteristics of reported cases of **chordoma** in the skull base and paracervical spine*

|              | Authors                    | N         | Median<br>total dose | Median<br>f/u (y) | Local control rate (%) |                    |      |
|--------------|----------------------------|-----------|----------------------|-------------------|------------------------|--------------------|------|
|              |                            |           |                      |                   | 3-y                    | 5-y                | 10-y |
| Photon       | Catton et al.              | 24        | 50.0                 | 5.2               |                        | 23                 | 15   |
|              | Romero et al.              | 18        | 50.1                 | 3.1               |                        | 17                 |      |
|              | Forsyth et al.             | 39        | 50.0                 | 8.3               |                        | 39                 | 31   |
|              | Magrini et al.             | 12        | 58.0                 | 6.0               |                        | 25                 | 25   |
| Proton       | Munzenrider et al. (MGH)   | 169       | 66-83                | 3.4               |                        | 73                 | 54   |
| (+/- photon) | Noel et al (CPO)           | 100       | 67.0                 | 2.6               | 86 (2-y)               | 54 (4-y)           |      |
|              | Hug et al. (MGH: 2002)     | 33        | 71.9                 | 2.8               | 67                     | 59                 |      |
|              | Hiroshi I et al (Tsukuba)  | 13        | 72.0                 | 5.8               | 67                     | 46                 |      |
| Helium       | Castro et al. (LB)         | 53        | 65.0                 | 4.3               |                        | 63                 |      |
| Carbon       | Shults-Ertner et al. (GSI) | 96        | 60.0                 | 2.6 (Mean)        | 81                     | 70                 |      |
|              | <b>NIRS</b>                | <b>29</b> | <b>48-60.8</b>       | <b>3.7</b>        |                        | <b>89 (SE ±10)</b> |      |
|              | <b>NIRS</b>                | <b>19</b> | <b>60.8</b>          | <b>2.7</b>        |                        | <b>93 (SE ±07)</b> |      |

# Conclusion

1. The carbon ion dose in 60.8 GyE improves local control. Additionally, we did not observe severe toxicity for the critical organs such as brainstem, spinal cord and optic nerves.
2. Carbon ion radiotherapy for chordoma compared with photon, proton and helium ion radiotherapy will deliver a high local control rates with low toxicity to the surrounding normal tissues.